$0.19
Value $13M
ABOS and ABT stock compared: price, dividend, valuation and results, from SEC filings.
$0.19
Value $13M
$103.00
Value $179B
Acumen Pharmaceuticals (ABOS) has a market value of $13M and Abbott Laboratories (ABT) $179B. Over the last year, with dividends, ABOS moved -87.9% and ABT -16.3%. Dividend yield: ABOS none, ABT 2.45%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABOS$13M
ABT$179B
ABT is 13,290 times ABOS
Revenue, 12 months
ABOS–
ABT$48.2B
Net income, 12 months
ABOS-$104M
ABT$4.7B
Operating margin
ABOS–
ABT13.8%
ROIC
ABOS-96.3%
ABT6.3%
102.6 points apart
P/E
ABOS–
ABT38.1
Dividend yield
ABOS0.0%
ABT2.5%
2.5 points apart
5-year return
ABOS-98.1%
ABT-10.3%
87.8 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABOS-98.1%
ABT-10.3%
| Period | ABOSWith dividends | ABTWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | -87.9%Price -87.9% | -16.3%Price -18.4% |
| 3 years since November 20, 2023 | -92.1%-57.0% a yearPrice -92.1% | +8.4%+2.7% a yearPrice +1.8% |
| 5 years since November 19, 2021 | -98.1%-54.8% a yearPrice -98.1% | -10.3%-2.1% a yearPrice -18.8% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABOSAcumen PharmaceuticalsABTAbbott Laboratories
| Price | $0.19 | $103.00 |
|---|---|---|
| Market value | $13M | $179B |
| Enterprise value (EV) | – | $206B |
| P/E | – | 38.1 |
| P/E, 5-year median | – | 33.7 |
| P/B | 0.4 | 3.5 |
| EV/EBIT | – | 31.0 |
| Free cash flow yield | – | 3.8% |
| Revenue, 12 months | – | $48.2B |
|---|---|---|
| Net income, 12 months | -$104M | $4.7B |
| Free cash flow, 12 months | -$88M | $6.8B |
| Earnings per share, 12 months | -$1.54 | $2.69 |
| Revenue growth, year on year | – | 5.7% |
| Revenue growth a year, past | – | +5.1%over 5 years |
| EPS growth a year, past | – | +8.3%over 5 years |
| Gross margin | – | 56.9% |
|---|---|---|
| Operating margin | – | 13.8% |
| Net margin | – | 9.8% |
| ROIC | -96.3% | 6.3% |
| ROE | -151.6% | 9.1% |
| Cash | $79M | $4.3B |
|---|---|---|
| Total debt | – | $31.2B |
| Net debt / EBITDA | – | 3.3 |
| Interest cover | -29.1× | 6.7× |
| Dividend yield | – | 2.5% |
|---|---|---|
| Dividend per share, 12 months | – | $2.52 |
| Dividend growth a year, past | – | +10.4%over 5 years |
| Buyback yield | – | 0.5% |
| Shareholder yield | – | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Abbott Laboratories ($179B) is about 13,289.7 times Acumen Pharmaceuticals ($13M), at today's prices.
Since November 19, 2021, ABOS's price moved -98.1% and ABT's -18.8%. With dividends: ABOS -98.1% (-54.8% a year), ABT -10.3% (-2.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Acumen Pharmaceuticals and 2.45% for Abbott Laboratories. Over the last twelve months they paid – and $2.52 per share.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.